The epidermal growth factor receptor (EGFR) inhibitors represent a relatively new class of cancer agents that also provide new challenging side effects for cancer patients. This article reviews the clinical aspects of EGFR inhibitor-induced rash, which occurs most commonly with use of these agents, and discusses some of the challenges faced in attempting palliation treatment. (copyright) Current Medicine Group LLC 2008.
CITATION STYLE
B.M., S., & A., J. (2008). Rash from EGFR inhibitors: Opportunities and challenges for palliation. Current Oncology Reports, 10(4), 304–308. Retrieved from http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L354099624
Mendeley helps you to discover research relevant for your work.